G-CSF（颗粒细胞增生因子）市场报告：2031 年趋势、预测与竞争分析

全球 G-CSF（颗粒细胞增生因子）市场前景光明，在肿瘤疾病、血液疾病、生长激素缺乏症、慢性疾病和自体免疫疾病市场都存在机会。预计到 2031 年，全球 G-CSF（颗粒细胞增生因子）市场规模将达到 107 亿美元，2025 年至 2031 年的复合年增长率为 3.2%。该市场的主要驱动力是癌症发病率的上升和医疗保健成本的上升。

• Lucintel 预测胶囊在预测期内将出现高速成长。
• 根据应用，肿瘤学预计将实现最高成长。
• 根据地区，预计北美将在预测期内实现最高成长。

G-CSF（颗粒细胞增生因子）市场的策略性成长机会

G-CSF（颗粒细胞增生因子）市场呈现多种策略成长机会。以下五点似乎是最重要的：

• 多样化的市场成长：随着医疗保健系统的改善，癌症发生率不断上升，靶向 G-CSF 製剂可能会在新兴国家显着增长。在这些地区引入生物相似药将增加市场进入和收益。
• 联合治疗的开发：将 G-CSF 与其他抗癌药物结合，可以实现 G-CSF 的最佳剂量。这项策略将有利于寻求解决嗜中性白血球低下症的医疗保健专业人员，因为单独使用 G-CSF 往往是不够的。
• 研发投资：进一步的研发投资可能会带来新的先进 G-CSF 配方的开发。这种方法可以帮助满足不断变化的患者需求并提高依从性。
• 伙伴关係和协作：与生物技术公司和研究机构建立策略联盟有助于有效开发新型 G-CSF 配方。透过采用尖端技术和新理念，您可以加强行销策略并刺激市场成长。
• 利用数位健康工具：在 G-CSF 治疗管理中利用数位健康策略可能会改善治疗结果。此外，针对慢性病管理客製化的远端医疗和行动应用程式可以帮助提高依从性并增强治疗效果。

这些策略性成长机会可以透过增加治疗的​​可用性、刺激新方法和改善患者医疗保健计划来促进 G-CSF（颗粒细胞增生因子）市场的发展。因此，对于 G-CSF 领域的市场参与企业来说，为了在这个竞争激烈的市场中取得成功，这些趋势至关重要。

G-CSF（颗粒细胞增生因子）市场驱动因素与挑战

G-CSF（颗粒细胞增生因子）市场的成长受到多种驱动因素​​和挑战的显着影响。这些因素对于希望在这个市场上运作的相关人员来说至关重要。

推动 G-CSF（颗粒细胞增生因子）市场的因素有：

• 癌症发生率上升：G-CSF（颗粒细胞增生因子）市场分化的主要原因是癌症人口的增加，这增加了对 G-CSF 疗法（例如针对化疗引起的嗜中性白血球低下症的疗法）的市场。随着癌症发生率的上升，透过使用有效的检测方法为患者提供适当的护理已成为当务之急。
• 生物技术的进步：生物技术领域正在进行许多创新，以开发新型 G-CSF 配方。随着新配方和给药途径的改变使治疗更加有效并鼓励更多患者继续治疗，市场正在扩大。
• 提高对嗜中性白血球低下症管理的认识：医疗保健专业人员和患者对管理嗜中性白血球低下症的必要性的认识不断提高，从而增加了 G-CSF 的使用。现在，我们对患者进行了有关该疾病的教育，并且患者在早期阶段就寻求帮助，从而获得了更好的治疗效果。
• 支持性法律规范：监管机构正在积极主动地与公司合作，以生产和获得新的 G-CSF 产品的核准。这种支持将加速新治疗方法的市场推广。
• 生物相似药创新：随着生物相似药在 G-CSF（颗粒细胞增生因子）市场中不断获得份额，竞争将会加剧，价格将会下降。这将使患者更容易接受 G-CSF 治疗，进而导致 G-CSF 治疗的快速普及。

G-CSF（颗粒细胞增生因子）市场的挑战如下：

• 开发成本高：开发和商业化 G-CSF 产品需要大量资金，这可能会阻碍进一步的投资和创新。在这样一个资本密集的行业中，这可能会对新参与企业造成阻碍。
• 市场饱和：学名药和生物相似药的激增可能导致市场饱和，使差异化变得困难。为了在这种竞争环境中生存，公司需要积极主动地采用创新。
• 监管障碍：试图进入市场的新型 G-CSF 产品可能会因监管流程的复杂性而受到阻碍。严格的安全和功效法规可能会延迟产品上市并增加开发成本。

G-CSF（颗粒细胞增生因子）市场的趋势受到癌症发生率上升、生物技术进步和生物相似药扩张等因素的影响。然而，高昂的开发成本、市场饱和和复杂的法规等挑战可能会限製成长和创新。该地区的相关人员需要在利用市场驱动力的同时应对这些挑战。这些力量预计将影响 G-CSF（颗粒细胞增生因子）市场的供需平衡。

目录

第一章执行摘要

2. 全球颗粒细胞增生因子(G-CSF) 市场：市场动态

• 简介、背景和分类
• 供应链
• 产业驱动力与挑战

第三章 2019年至2031年市场趋势及预测分析

• 宏观经济趋势（2019-2024）及预测（2025-2031）
• 全球G-CSF（颗粒细胞增生因子）市场趋势（2019-2024年）及预测（2025-2031年）
• 按类型：G-CSF（颗粒细胞增生因子）市场
  • 胶囊
  • 锭剂
  • 其他的
• 全球G-CSF（颗粒细胞增生因子）市场应用状况
  • 肿瘤疾病
  • 血液系统疾病
  • 生长激素缺乏症
  • 慢性及自体免疫疾病
  • 其他的

第四章2019年至2031年区域市场趋势与预测分析

• 按地区：G-CSF（颗粒细胞增生因子）市场
• 北美G-CSF（颗粒细胞增生因子）市场
• 欧洲G-CSF（颗粒细胞增生因子）市场
• 亚太颗粒细胞增生因子（G-CSF）市场
• 世界其他地区G-CSF（颗粒细胞增生因子）市场

第五章 竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 按类型：全球 G-CSF（颗粒细胞增生因子）市场的成长机会
  • 按应用：全球G-CSF（颗粒细胞增生因子）市场的成长机会
  • 按地区：全球 G-CSF（颗粒细胞增生因子）市场的成长机会
• 全球G-CSF（颗粒细胞增生因子）市场的新趋势
• 战略分析
  • 新产品开发
  • 全球G-CSF（颗粒细胞增生因子）市场容量不断扩大
  • 全球G-CSF（颗粒细胞增生因子）市场的合併、收购及合资企业
  • 认证和许可

第七章主要企业简介

• Amgen
• Coherus Biosciences
• Sandoz
• Biocon/Mylan
• Teva Pharmaceuticals
• Chugai Pharma
• Intalfarmaco
• Pfizer
• Sun Pharmaceutical Industries
• BeyondSpring

The future of the global G-CSF (granulocyte colony stimulating factor) market looks promising with opportunities in the oncological disease, blood disorder, growth hormone deficiencies, and chronic and autoimmune disorder markets. The global G-CSF (granulocyte colony stimulating factor) market is expected to reach an estimated $10.7 billion by 2031 with a CAGR of 3.2% from 2025 to 2031. The major drivers for this market are the increasing prevalence of cancer and rise in healthcare expenses.

• Lucintel forecasts that, within the type category, the capsule is expected to witness higher growth over the forecast period.
• Within the application category, oncological disease is expected to witness the highest growth.
• In terms of regions, North America is expected to witness the highest growth over the forecast period.

Gain Valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the G-CSF (Granulocyte Colony Stimulating Factor) Market

Numerous changes are being witnessed in the G-CSF (granulocyte colony stimulating factor) market, and these changes will help revolutionize the treatment model and market landscape. Five such trends are summarized below.

• Increased Focus on Biosimilars: Competition in the G-CSF (granulocyte colony stimulating factor) market is being enhanced by the rise of biosimilars, resulting in lower prices and higher patient rates. With a couple of biosimilars already on the market, it is easier for healthcare providers to manage patients appropriately, which enhances adherence to treatment and improves overall health.
• Personalized Medicine Approaches: A growing trend in personalized medicine is also affecting G-CSFs. Different patients presenting the same symptoms may have unique biological factors that should be considered. Therefore, the development of these new therapies becomes more targeted while limiting toxicity and enhancing the quality of life for patients.
• Innovative Delivery Methods: New drug delivery systems, such as long-acting formulations and delivery via subcutaneous injection, are being introduced to increase compliance. These innovations also reduce the frequency of treatment, which is especially helpful for patients undergoing chemotherapy.
• Regulatory Support and Guidance: Fundamental changes in medicine and health practices have led to regulations stipulating the use and administration of G-CSFs, enhancing care. Various guidelines also encourage monitoring, which is important in standardizing treatment practices among healthcare providers and ensuring that the necessary skills are available to treat patients optimally.
• Integration of Digital Health Solutions: Digital health technologies, including telehealth and mobile applications for health management, are being adopted to assist in patient care during G-CSF therapy. These tools help improve patient adherence and control side effects through enhanced interactions with healthcare providers.

These trends are altering the G-CSF (granulocyte colony stimulating factor) market by spurring creativity, increasing the number of patients who can be treated, and improving treatment outcomes. To deliver patient care effectively in this expanding market, these factors will be crucial in determining and developing future therapeutic approaches.

Recent Developments in the G-CSF (Granulocyte Colony Stimulating Factor) Market

Within the G-CSF (granulocyte colony stimulating factor) market, there have been remarkable developments that address therapeutic efficacy and treatment parameters. Below are several noteworthy advancements in this field.

• Launch of New Biosimilars: The entry of several biosimilars has resulted in fierce competition in the G-CSF (granulocyte colony stimulating factor) market, which has led to reduced prices and increased market penetration. This enables providers to offer more treatment options to patients without sacrificing quality.
• Advancements in Long-Acting Formulations: Novel long-acting G-CSF formulations are gaining traction, requiring administration at longer intervals. These modifications increase patient compliance, especially for those undergoing chemotherapy, improving convenience and adherence rates.
• Integration of Telehealth Solutions: Patients undergoing G-CSF therapy benefit from remote monitoring and consultations through telehealth platforms. This promotes patient participation and facilitates the timely enhancement of care.
• Clinical Trials for New Indications: New trials are investigating the use of G-CSF for patients with severe infections or autoimmune diseases. The expanded application of G-CSF could address unmet medical needs in various patient populations.
• Regulatory Approvals for Combination Therapies: New application regions for G-CSF have approved combination therapy protocols, suggesting that consolidating treatment strategies could improve outcomes, particularly in complicated clinical situations, and provide clinicians with a wider range of treatment options.

These changes are contributing to positive developments in the G-CSF (granulocyte colony stimulating factor) market, enhancing treatment accessibility, improving patient adherence, and broadening treatment options. As these trends continue, they will play an increasingly important role in shaping the future of the G-CSF (granulocyte colony stimulating factor) market.

Strategic Growth Opportunities for G-CSF (Granulocyte Colony Stimulating Factor) Market

The G-CSF (granulocyte colony stimulating factor) market presents several strategic growth opportunities. The following five appear to be the most critical.

• Diverse Market Growth: Targeted G-CSF products are likely to experience significant growth in developing countries, where cancer incidence is rising alongside improvements in healthcare systems. The introduction of biosimilars in these regions will increase market access and revenue.
• Development of Combination Therapies: The optimal administration of G-CSF can be achieved by combining it with other oncological drugs. This strategy will benefit healthcare professionals seeking solutions for neutropenia, which often requires more than just G-CSF administration.
• Investment in Research and Development: Further investment in R&D could lead to the development of new and advanced G-CSF products. This approach will address the changing needs of patients and improve compliance.
• Partnerships and Collaborations: Strategic collaborations with biotech companies and research organizations will help efficiently develop novel G-CSF products. Shared efforts can enhance marketing strategies by incorporating cutting-edge technologies and new ideas, spurring market growth.
• Utilization of Digital Health Tools: The use of digital health strategies in managing G-CSF therapy is likely to improve therapeutic outcomes. Telemedicine and mobile applications tailored for chronic illness management will also help improve compliance and enhance the effectiveness of treatment.

These strategic growth opportunities can boost the G-CSF (granulocyte colony stimulating factor) market by increasing treatment availability, stimulating new approaches, and improving healthcare planning for patients. Therefore, these trends are essential for market participants in the G-CSF sector to consider for success in this competitive market.

G-CSF (Granulocyte Colony Stimulating Factor) Market Driver and Challenges

The growth of G-CSF (granulocyte colony stimulating factor) market is largely affected by numerous drivers and most of the challenges. These factors are very critical to the stakeholders who wish to operate in this market.

The factors responsible for driving the G-CSF(granulocyte colony stimulating factor) market include:

• Rising Cancer Incidence: The main source of differentiation for G-CSF (granulocyte colony stimulating factor) market is the increasing cancer population which increases the market of the G-CSF therapies such as the ones targeting chemotherapy-induced neutropenia. Because of the rising incidences of cancer, the focus on providing proper care to the patients through the use of effective assays is becoming essential.
• Advancements in Biotechnology: There are many technological innovations in the biotechnology field for the development of novel G-CSF products. New formulations and change in the routes of administration make treatments more effective and more patients adhere to therapy thus widening the market.
• Growing Awareness of Neutropenia Management: There is an increase in the healthcare providers' and Zulfiqar Ahmed patients' appreciation regarding the need to manage neutropenia thereby increasing the use of G-CSF. Education is upon patients in relation to the disease which encourages them to seek help very early on thus getting better results.
• Supportive Regulatory Frameworks: Regulatory bodies are in contact with firms either prospectively or retrospectively encouraging them to undertake processes of making new G-CSF products and getting them approved- this validates and creates a desideratum for development. This support expedites the introduction into the market of new medicinal treatments.
• Innovation of Biosimilars: As biosimilar products continue to gain a larger share in the G-CSF (granulocyte colony stimulating factor) market, competition heats up and prices decline. This makes it easier for patients to undergo G-CSF which in turn brings about the fast uptake of G-CSF therapy methods into practice.

Challenges in the G-CSF (granulocyte colony stimulating factor) market are:

• High Development Costs: Developing and commercializing a G-CSF product is capital-intensive, which may discourage further investment and innovation. In such a capital-heavy industry, this may deter new market players.
• Market Saturation: The proliferation of generics and biosimilars may lead to market saturation, where differentiation becomes difficult. Organizations must actively introduce innovations to survive in this competitive environment.
• Regulatory Hurdles: The complexity of regulatory processes sometimes interferes with the ability of companies to launch new G-CSF products. Strict safety and efficacy regulations may delay product availability in the market and inflate development costs.

The G-CSF (granulocyte colony stimulating factor) market trends are influenced by factors such as increasing cancer incidences, technological advances in biotechnology, and the growing range of biosimilars. However, issues like high development costs, market saturation, and complex regulations could limit growth and innovation. Stakeholders in the region will need to address these challenges while capitalizing on market drivers. These forces will shape the balance between supply and demand in the G-CSF (granulocyte colony stimulating factor) market.

List of G-CSF (Granulocyte Colony Stimulating Factor) Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies G-CSF (granulocyte colony stimulating factor) companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the G-CSF (granulocyte colony stimulating factor) companies profiled in this report include-

• Amgen
• Coherus Biosciences
• Sandoz
• Biocon/Mylan
• Teva Pharmaceuticals
• Chugai Pharma
• Intalfarmaco
• Pfizer
• Sun Pharmaceutical Industries
• BeyondSpring

G-CSF (Granulocyte Colony Stimulating Factor) by Segment

The study includes a forecast for the global G-CSF (granulocyte colony stimulating factor) market by type, application, and region.

G-CSF (Granulocyte Colony Stimulating Factor) Market by Type [Analysis by Value from 2019 to 2031]:

• Capsule
• Tablet
• Others

G-CSF (Granulocyte Colony Stimulating Factor) Market by Application [Analysis by Value from 2019 to 2031]:

• Oncological Disease
• Blood Disorder
• Growth Hormone Deficiencies
• Chronic and Autoimmune Disorder
• Others

G-CSF (Granulocyte Colony Stimulating Factor) Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the G-CSF (Granulocyte Colony Stimulating Factor) Market

The Granulocyte Colony Stimulating Factor (G-CSF) market is expected to grow rapidly due to factors such as advancements in biotechnology, increasing awareness of neutropenia management, and the rising demand for cancer therapeutics. G-CSF plays a crucial role in boosting neutrophil counts, which is vital for chemotherapy patients and those suffering from various blood diseases. Drug formulation innovations and regulatory improvements in countries like the USA, China, Germany, India, and Japan are enhancing patient care and treatment outcomes.

• USA: G-CSF formulations such as pegfilgrastim have found widespread use in the U.S. among oncology patients due to the rise in chemotherapy-induced neutropenia. Several G-CSF biosimilars have been approved by the FDA, increasing market competition and availability. Recent clinical trials are exploring new methods of administration, including subcutaneous injections, to improve patient convenience. Additionally, there is a growing focus on individualized treatment plans that enhance the effectiveness of G-CSF therapies.
• China: The G-CSF (granulocyte colony stimulating factor) market in China is expanding rapidly due to the increasing number of cancer patients and the aging population. To support the research and manufacturing of G-CSF drugs, the government has implemented favorable policies, leading to an increase in the number of new biosimilars on the market. New strategies have been introduced to ensure the safe use of G-CSF in cancer patients, while local pharmaceutical companies are collaborating with global biotech firms to improve product access.
• Germany: Germany is making significant strides in G-CSF therapies, with ongoing efforts to develop advanced delivery systems and formulations. Recent studies focus on improving treatment plans to achieve the desired outcomes while minimizing toxicity. The country has also seen a rise in biosimilar development, which is likely to improve access to treatment and lower costs for patients. Regulatory bodies are actively advocating for best practices in G-CSF use, helping standardize care for oncology patients.
• India: The G-CSF (granulocyte colony stimulating factor) market in India is growing due to the increasing incidence of cancer and improved healthcare access. Neutropenic patients now have more treatment options as affordable G-CSF biosimilars become available. Campaigns to raise awareness of chemotherapy side effect management among healthcare providers are gaining traction. Additionally, efforts by Indian pharmaceutical companies, along with potential collaborations with international organizations, are accelerating the development of novel G-CSF formulations.
• Japan: Japan's G-CSF (granulocyte colony stimulating factor) market is focused on drug development with the support of advanced technologies. New long-acting G-CSF formulations that require less frequent administration are improving patient adherence to treatment. Additionally, the regulatory environment is becoming more favorable for biosimilars, speeding up their approval process. Clinical studies are increasingly focused on tailoring G-CSF therapy to specific patient conditions, which is expected to enhance treatment efficacy for cancer patients.

Features of the Global G-CSF (Granulocyte Colony Stimulating Factor) Market

Market Size Estimates: G-CSF (granulocyte colony stimulating factor) market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecasts (2025 to 2031) by various segments and regions.

Segmentation Analysis: G-CSF (granulocyte colony stimulating factor) market size by type, application, and region in terms of value ($B).

Regional Analysis: G-CSF (granulocyte colony stimulating factor) market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the G-CSF (granulocyte colony stimulating factor) market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the G-CSF (granulocyte colony stimulating factor) market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the G-CSF (granulocyte colony stimulating factor) market by type (capsule, tablet, and others), application (oncological disease, blood disorder, growth hormone deficiencies, chronic and autoimmune disorder, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global G-CSF (Granulocyte Colony Stimulating Factor) Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global G-CSF (Granulocyte Colony Stimulating Factor) Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global G-CSF (Granulocyte Colony Stimulating Factor) Market by Type
  • 3.3.1: Capsule
  • 3.3.2: Tablet
  • 3.3.3: Others
• 3.4: Global G-CSF (Granulocyte Colony Stimulating Factor) Market by Application
  • 3.4.1: Oncological Disease
  • 3.4.2: Blood Disorder
  • 3.4.3: Growth Hormone Deficiencies
  • 3.4.4: Chronic and Autoimmune Disorder
  • 3.4.5: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global G-CSF (Granulocyte Colony Stimulating Factor) Market by Region
• 4.2: North American G-CSF (Granulocyte Colony Stimulating Factor) Market
  • 4.2.1: North American Market by Type: Capsule, Tablet, and Others
  • 4.2.2: North American Market by Application: Oncological Disease, Blood Disorder, Growth Hormone Deficiencies, Chronic and Autoimmune Disorder, and Others
• 4.3: European G-CSF (Granulocyte Colony Stimulating Factor) Market
  • 4.3.1: European Market by Type: Capsule, Tablet, and Others
  • 4.3.2: European Market by Application: Oncological Disease, Blood Disorder, Growth Hormone Deficiencies, Chronic and Autoimmune Disorder, and Others
• 4.4: APAC G-CSF (Granulocyte Colony Stimulating Factor) Market
  • 4.4.1: APAC Market by Type: Capsule, Tablet, and Others
  • 4.4.2: APAC Market by Application: Oncological Disease, Blood Disorder, Growth Hormone Deficiencies, Chronic and Autoimmune Disorder, and Others
• 4.5: ROW G-CSF (Granulocyte Colony Stimulating Factor) Market
  • 4.5.1: ROW Market by Type: Capsule, Tablet, and Others
  • 4.5.2: ROW Market by Application: Oncological Disease, Blood Disorder, Growth Hormone Deficiencies, Chronic and Autoimmune Disorder, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global G-CSF (Granulocyte Colony Stimulating Factor) Market by Type
  • 6.1.2: Growth Opportunities for the Global G-CSF (Granulocyte Colony Stimulating Factor) Market by Application
  • 6.1.3: Growth Opportunities for the Global G-CSF (Granulocyte Colony Stimulating Factor) Market by Region
• 6.2: Emerging Trends in the Global G-CSF (Granulocyte Colony Stimulating Factor) Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global G-CSF (Granulocyte Colony Stimulating Factor) Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global G-CSF (Granulocyte Colony Stimulating Factor) Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Amgen
• 7.2: Coherus Biosciences
• 7.3: Sandoz
• 7.4: Biocon/Mylan
• 7.5: Teva Pharmaceuticals
• 7.6: Chugai Pharma
• 7.7: Intalfarmaco
• 7.8: Pfizer
• 7.9: Sun Pharmaceutical Industries
• 7.10: BeyondSpring